Dr-Lal-Pathlabs Stock/Share Prices, Buy and Sell Dr-Lal-Pathlabs BSE Stocks

Market Snapshot

BSE Sensex: 40685.5 0.31%
BSE 500: 15539.3 0.33%
BSE 200: 5016.03 0.31%
BSE 100: 11993.48 0.33%
BSE Mid-Cap: 14976.1 0.59%
BSE Small-Cap: 15134.59 0.71%
BANKEX: 27785.94 -0.06%
BSE IT Sector: 21737.93 -0.24%
Nifty 50: 11930.35 0.28%
Nifty 500: 9780.35 0.36%
Nifty 200: 6144.05 0.34%
Nifty 100: 12006.1 0.29%
Nifty Midcap 100: 17306.2 0.79%
Nifty Small 100: 5994.1 0.62%
Nifty IT: 21523.6 0.51%
Nifty PSU Bank: 1319.65 0.47%

News:

Yes Bank posts Q2 PAT at Rs 12...
Tech Mahindra Q2 PAT declines ...
JSW Steel Q2 PAT slides 38% Yo...
Chennai Petroleum Corporation ...
Vishal Fabrics Ltd leads loser...

Dr Lal Pathlabs Ltd NSE / BSE
Healthcare, Mid Cap

Invest

23 Oct 2020 | 03:59 PM

2,300.40

70.60 (3.17%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

55.19%

Return (1Y)

Beaten S&P BSE Healthcare by 2.49%
More Volatile

2.7%

Standard Deviation (1Y)

Higher than S&P BSE Healthcare by 1.05%
Not so consistent

4/12

Months

underperformed S&P BSE Healthcare
AxisDirect View

No View

52 Week High-Low

2,330

1,182

News & Announcements

Dr Lal Pathlabs receives reaffirmation in credit ratings for bank facilities
74 days ago

Dr Lal Pathlabs receives reaffirmation in credit ratings for bank facilities

11 - Aug - 2020 12:00 AM | 74 days ago

Dr Lal Pathlabs has received reaffirmation in credit ratings from CRISIL as under -
Total bank facilities rated Rs 60 crore
Long term rating - CRISIL AA-/ Stable (Reaffirmed)
Short term rating - CRISIL A1+ (Reaffirmed)
Powered by Capital Market - Live News
Dr Lal Pathlabs consolidated net profit declines 51.70% in the June 2020 quarter
84 days ago

Dr Lal Pathlabs consolidated net profit declines 51.70% in the June 2020 quarter

01 - Aug - 2020 12:00 AM | 84 days ago

Net profit of Dr Lal Pathlabs declined 51.70% to Rs 28.40 crore in the quarter ended June 2020 as against Rs 58.80 crore during the previous quarter ended June 2019. Sales declined 20.64% to Rs 266.00 crore in the quarter ended June 2020 as against Rs 335.20 crore during the previous quarter ended June 2019.
Particulars Quarter Ended
Jun. 2020 Jun. 2019 % Var.
Sales 266.00 335.20 -21
OPM % 18.16 28.37 -
PBDT 56.00 105.70 -47
PBT 38.10 89.40 -57
NP 28.40 58.80 -52
Powered by Capital Market - Live News
Dr Lal Pathlabs grants 1.12 lakh stock options under RSUOs
85 days ago

Dr Lal Pathlabs grants 1.12 lakh stock options under RSUOs

31 - Jul - 2020 12:00 AM | 85 days ago

Dr Lal Pathlabs has granted 1,12,200 Restricted Stock Unit options (Options) under the Dr Lal Pathlabs Employee Restricted Stock Unit Plan 2016 (RSU 2016/ Plan) to its employees.
Powered by Capital Market - Live News
Dr. Lal PathLabs to declare Quarterly Result
92 days ago

Dr. Lal PathLabs to declare Quarterly Result

24 - Jul - 2020 12:00 AM | 92 days ago

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 31 July 2020.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Dr Lal Pathlabs Ltd has been the 2nd best in 3 years performance among stocks in Healthcare Sector
Dr Lal Pathlabs Ltd has given the 3rd best dividend yield 0.85 for 1 Year among stocks in Healthcare Sector
Dr Lal Pathlabs Ltd is trading very close to its All time High
Dr Lal Pathlabs Ltd is trading very close to its 52 Week High

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Jun. 2020	Jun. 2019	% Var.
Sales	266.00	335.20	-21
OPM %	18.16	28.37	-
PBDT	56.00	105.70	-47
PBT	38.10	89.40	-57
NP	28.40	58.80	-52

General Notifications

My Notifications

Research Notifications

Dr Lal Pathlabs Ltd NSE / BSE Healthcare, Mid Cap

2,300.40 70.60 (3.17%)

News & Announcements

Price vs Volume

Stock Trivia

Dr Lal Pathlabs Ltd NSE / BSE
Healthcare, Mid Cap

2,300.40

70.60 (3.17%)